Tricia Morphew, United States of America

Morphew Consulting, LLC Biostatistics

Poster Author Of 1 e-Poster

Online Abstracts Vaccines - Impact of Vaccine programs and Serotype Replacement C2 Impact of Vaccine programs and Serotype Replacement

Author Of 1 Presentation

INVASIVE PNEUMOCOCCAL DISEASE IN CHILDREN: CLINICAL DISCREPANCIES BETWEEN VACCINE AND NON-VACCINE SEROTYPES (ID 300)

Abstract

Background

Following introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), concern regarding protection against invasive pneumococcal disease (IPD) caused by serotypes (ST) 3 and, to a lesser degree, 19A has been raised. We hypothesized that PCV13 STs, specifically ST3, are strongly associated with respiratory (R)-IPD and rare in non-respiratory (NR)-IPD.

Methods

Clinical and isolate details from a prospective surveillance study of pediatric IPD in Orange County, CA (2010-2019) are presented. R-IPD and NR-IPD group differences were assessed using the Chi-square test.

Results

Serotype was available for 181 IPD cases, of which 37% were PCV13-STs (54% of 78 R-IPD, 24% of 103 NR-IPD, p<.001). Of these, 32 (48%) had received no PCV13 immunization with 26 (81%) having occurred during first half of study. ST3 (21% and 4%, p<.001) and ST19A (21% and 8%, p=.01) were recovered from R-IPD and NR-IPD cases, respectively. Combined ST3 and ST19A accounted for 76% of PCV13 isolates in R-IPD and 48% in NR-IPD, p=.02. Most PCV13-STs occurred during fall-winter (63%).

Conclusions

R-IPD was predominantly associated with PCV13-STs, particularly ST3 and ST19A. PCV13 R-IPD was more common during fall-winter. The role of winter respiratory viruses in nasopharyngeal colonization with PCV13-STs and the timing of booster PCV13 dosing should be further researched.

Hide